Combination therapy with rituximab in Waldenström macroglobulinemia
Study . | No. patients . | Regimen . | ORR, % . | NR duration, mo . |
|---|---|---|---|---|
| Owen et al1 | 43 | Fludarabine/rituximab | 82 | 17+ |
| Tam et al14 | 5 | Fludarabine/cyclophosphamide/rituximab | 80 | 30+ |
| Weber et al12 | 17 | Cladribine/cyclophosphamide/rituximab | 94 | 21+ |
| Hensel et al15 | 17 | Pentostatin/cyclophosphamide/rituximab | 90 | 12+ |
| Dimoupoulous et al16 | 34 | Dexamethasone/cyclophosphamide/rituximab | 78 | 18+ |
| Hunter et al18 | 13 | CHOP/rituximab | 77 | 9+ |
| Dimopoulous et al6 | 72 | CHOP/rituximab (vs CHOP) | 94 | 48+ |
Study . | No. patients . | Regimen . | ORR, % . | NR duration, mo . |
|---|---|---|---|---|
| Owen et al1 | 43 | Fludarabine/rituximab | 82 | 17+ |
| Tam et al14 | 5 | Fludarabine/cyclophosphamide/rituximab | 80 | 30+ |
| Weber et al12 | 17 | Cladribine/cyclophosphamide/rituximab | 94 | 21+ |
| Hensel et al15 | 17 | Pentostatin/cyclophosphamide/rituximab | 90 | 12+ |
| Dimoupoulous et al16 | 34 | Dexamethasone/cyclophosphamide/rituximab | 78 | 18+ |
| Hunter et al18 | 13 | CHOP/rituximab | 77 | 9+ |
| Dimopoulous et al6 | 72 | CHOP/rituximab (vs CHOP) | 94 | 48+ |
ORR indicates overall response rate; and NR, not reached.